RELATED CONTENT
IBA Molecular announced that it has merged with previous acquisition Mallinckrodt Nuclear Medicine LLC to form the new company Curium.
April 11, 2017 
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016, following the receipt of regulatory approvals.
January 30, 2017 
IBA (Ion Beam Applications S.A.) announced the sale of IBA Molecular (IBAM) in which IBA had a 40 percent stake, to funds advised by CapVest Partners LP (“CapVest”), has closed successfully.
March 29, 2016 
IBA (Ion Beam Applications S.A.) announced the completion of the divestiture of IBA Molecular North America Inc. (IBAM NA) to Illinois Health and Science (IHS), a non-profit healthcare system.
August 10, 2015 September 14, 2012 — IBA Molecular North America Inc., a manufacturer and distributor of PET imaging tracers, has announced the introduction of its Centers for Innovation, two unique facilities designed for advanced radiopharmaceutical contract development and manufacturing. The centers are located in Totowa and Somerset, N.J. Complementing these sites are IBA Molecular's production capabilities for isotopes such as I-124, F-18, Zr-89 and in the future, Cu-64 and Y-86. The centers are expected to play an important role in the development of a new generation of disease-specific tracers and companion theragnostics.
September 14, 2012 
April 5, 2012 - SK Capital Partners, a U.S. based private investment firm, and IBA (Ion Beam Applications S.A.) announced
that they have closed on their previously announced agreement to create IBA Molecular, a jointly-owned company derived from IBA’s worldwide radiopharmaceutical division. IBA Molecular is a worldwide leader in the manufacturing and distribution of radioactive isotopes used for medical imaging and therapy, with over 50 locations in the United States, Europe and Asia and employs over 1,000 people. The transaction is valued at approximately €180 million ($239 million). SK Capital will own 60 percent of the recapitalized entity and IBA will retain a 40 percent stake.
April 05, 2012 
April 29, 2009 – The FDA cleared of a new generation of patient positioning system (PPS) developed by Ion Beam Applications S.A. (IBA) and ProCure Treatment Centers Inc. (ProCure), which is designed to improve proton therapy.
April 29, 2009 August 13, 2008 – Ion Beam Applications (IBA) and NeuroSurvival Technologies Ltd. (NST) today announced the signing of a ...
August 12, 2008 June 18, 2007 – IBA Molecular has begun delivery of Iodine-124 to PET Centers in Europe. The positron emitter has been ...
June 18, 2007 June 5, 2007 - IBA Molecular announced the launch of www.getaPETscan.com, a new patient-focused Web Site that aims to ...
June 04, 2007